Search Results
Dec 28, 2025, 21:24 ET Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC "Blockbuster" Therapy
Safety and DLT evaluation on CX-54612. RP2D for on CX-54613. ORR4. CX-5461 PK5. Effect on MYC-aberrant lymphoma gene expression2024: USD 4.9BCAGR: 5.79%2035:
More news about: Senhwa Biosciences, Inc.
Dec 28, 2025, 19:10 ET CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596
genes such as NKG2A, TRAC, and B2M, CT0596 is designed to reduce the risk of graft-versus-host disease (GvHD) and host immune rejection. Additional gene editing further blocks host natural killer (NK) cell-mediated rejection, thereby aiming to enhance the product's efficacy and safety profile.Investigator-initiated
More news about: CARsgen Therapeutics
Dec 25, 2025, 04:02 ET Gene Solutions 於 ESMO Asia Congress 2025 成功舉辦 AI 驅動多組學液態活檢專題研討會，並榮獲兩項最佳海報獎
2025年12月25日 /美通社/ -- 領先的基因檢測公司 Gene Solutions 在 2025 年的歐洲腫瘤內科學會（ESMO）亞洲大會上取得多項重要成果。該大會於 12 月 5 日至 7 日在新加坡舉行。在该大会上，公司举办了一場座無虛席的專題研討會，发布了七篇科學摘要（其中兩篇榮獲「最佳海報」獎項）以及在公司展位上與來自亞太地區的數千名腫瘤科醫師的深入交流。2025 年對 Gene Solutions 而言是成果豐碩的一年，公司在印度、土耳其、中国台灣、香港特別行政區及中國大陸的業務布局以及和合作夥伴的關係在持續擴展。Gene Solutions 开发了亞洲首項多癌早期檢測（MCED）技術推動精準腫瘤學發展，該技術已在一項涵蓋
More news about: Gene Solutions Genomics Pte Ltd
Dec 25, 2025, 03:45 ET China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval
chemotherapy;For the first-line treatment of unresectable locally advanced or metastatic non-squamous non-small cell lung cancer lacking EGFR or ALK driver gene mutations;For the treatment of patients with EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer who progressed
More news about: Innovent Biologics
Dec 24, 2025, 10:07 ET Nearly One-in-Four Workers 'Functionally Unemployed,' Says Ludwig Institute
@LISEP_org.About Gene LudwigIn addition to his role as LISEP chair, Gene Ludwig is a managing partner of Canapi LLC, a financial technology venture fund. He is the founder and CEO of Ludwig
More news about: Ludwig Institute for Shared Economic Prosperity
Dec 23, 2025, 15:30 ET QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
On November 3, 2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application ("BLA") submission. Specifically,
More news about: Kessler Topaz Meltzer & Check, LLP
Dec 23, 2025, 10:11 ET AVIATION ICON CLAY LACY RECOGNIZED WITH PEARL HARBOR AVIATION MUSEUM'S SPIRIT OF AVIATION AWARD
his passion for flight. Notable people such as Neil Armstrong, Joe Clark, Bob Hoover, Bruce McCaw, Bud Anderson, Bill Lear, Barron Hilton, Si Robin, Gene Cernan, Carroll Shelby, Danny Kaye, and Allen Paulson formed a network of camaraderie that they all enjoyed for years.He flew countless celebrities,
More news about: Pearl Harbor Aviation Museum
Dec 22, 2025, 08:36 ET Origin Agritech Holds Annual R&D and Operations Management Conference, Establishes 2026 Strategic Priorities
market needs," stated Mr. Bill Deng, Vice President and Head of R&D. "By combining traditional breeding expertise with AI-powered analytics and gene editing capabilities, we're accelerating the development timeline for high-value traits while maintaining rigorous quality standards."Distinguished
More news about: Origin Agritech Limited
Dec 22, 2025, 08:00 ET Beyond Celiac Investments Announces Funding of RheumaGen to Accelerate Treatments Towards a Cure in Celiac Disease
of Beyond Celiac, has made a Series A-1 preferred stock investment in RheumaGen, a cell and gene therapy company focused on editing the human leukocyte antigen (HLA) to develop one-time, curative cell and gene therapies for common autoimmune diseases. The investment will be used to advance their celiac
More news about: Beyond Celiac
Dec 22, 2025, 08:00 ET RheumaGen Announces Funding Agreement with Beyond Celiac Investments to Accelerate Treatments Towards a Cure in Celiac Disease
program through early development as a potential transformational gene therapyAURORA, Colo., Dec. 22, 2025 /PRNewswire/ -- RheumaGen, Inc., a cell and gene therapy company engineering a new class of therapeutics to cure
More news about: RheumaGen, Inc.
Dec 21, 2025, 07:20 ET T-MAXIMUM Pharmaceutical's Allogeneic CAR-T Therapy MT027 Receives FDA IND Clearance to Proceed to Phase II clinical Trial for Recurrent Glioblastoma
currently no effective treatments. The company brings together a seasoned team with expertise in immunotherapy, gene editing, and biopharmaceutical industrialization. Leveraging its fully proprietary gene-edited allogeneic immune cell platform, T-MAXIMUM has successfully overcome key challenges in allogeneic
More news about: T-MAXIMUM PHARMACEUTICAL
Dec 19, 2025, 14:46 ET Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy,
More news about: Hansa Biopharma AB
Dec 19, 2025, 14:43 ET Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy,
More news about: Hansa Biopharma AB
Dec 19, 2025, 10:00 ET The Donald M. Ephraim Sun & Stars International Film Festival© To Honor PB County Film Commissioner Michelle Hillery with Inaugural 'Ephraim/Sriberg Award for Cinematic Excellence'
with a tender and all-encompassing sense of humor," says SASIFF Artistic Director Barbara Scharres, the former director of programming at the Gene Siskel Film Center at the School of the Art Institute of Chicago.About The Donald M. Ephraim Sun & Stars International Film Festival:The
More news about: MorseLife
Dec 19, 2025, 09:03 ET L'Oréal Dermatological Beauty and CeraVe Join Massachusetts General Hospital to Announce First-Ever Endowed Chair in Global Health Dermatology
efforts, seeing firsthand her commitment to creating long-lasting change around the world," said CeraVe Global SVP, Medical Affairs & Communications Gene Colón. "As a brand that believes everyone deserves access to skin health and resources, CeraVe sees this endowed Chair as an opportunity to work alongside
More news about: CeraVe
Dec 19, 2025, 08:30 ET Xtalks Life Science Podcast Wraps Up 2025 with Deep Dives into Drug Development, Regulation, Clinical Trials and Innovation, Sets Sights on a Transformative 2026 by Xtalks
neurodegenerative diseases and oncology to autoimmune diseases and ocular diseases, as well as technologies such as AI-enabled drug discovery, cell and gene therapies and digital health tools. Looking ahead to 2026, expect more informative conversations around themes shaping drug development, clinical trials,
More news about: Xtalks
Dec 19, 2025, 07:45 ET BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
pharmacological chaperone of alpha-Galactosidase A (alpha-Gal A) for the treatment of Fabry disease in adults who have amenable galactosidase alpha gene (GLA) variants. In these patients, Galafold works by stabilizing the body's own dysfunctional enzyme so that it can clear the accumulation of disease
More news about: BioMarin Pharmaceutical Inc.
Dec 19, 2025, 07:41 ET Chonnam National University Scientists Discover a Molecular Switch That Protects Crops from Freezing Cold
rewiring of a hormone signaling pathway, triggering the breakdown of auxin/indole acetic acid repressors, releasing ARF7 and ARF19 to activate the master gene CRF3, helping plants survive the cold. This offers a new path to breeding crops that remain productive even under unpredictable climate conditions.
More news about: Chonnam National University
Dec 19, 2025, 00:00 ET MEDIPOST Announces the Exclusive Commercialization License Agreement with Teikoku Seiyaku for Knee Osteoarthritis Treatment CARTISTEM® in Japan
capabilities spanning across discovery research with product and clinical development of allogeneic cell therapy pipelines, cord blood banking, and cell and gene therapy contract development and manufacturing (CDMO) business portfolios. MEDIPOST successfully commercialized the world's first regulatory-approved
More news about: MEDIPOST
Dec 18, 2025, 16:30 ET Pangaea Logistics Solutions Ltd. Appoints Eugene I. Davis to its Board of Directors
International Inc. and as a member of the Board of Directors of Spirit Aviation Holdings Inc., where he is the chairman of the Audit Committee."Gene brings a strong track record of helping boards and management teams refine strategy and drive value creation," said Richard du Moulin, Chairman of the
More news about: Pangaea Logistics Solutions LTD
Dec 18, 2025, 14:00 ET Pesquisa inédita revela o "DNA do Caramelo" e identifica as raças e características mais comuns do cão mais querido do Brasil
cães apresentaram ao menos uma variante genética ligada a distúrbios de saúde e, em 97% desses casos, eram apenas portadores, com uma única cópia do gene alterado. Como essas doenças hereditárias são recessivas, elas só se manifestam com duas cópias, ou seja, esses cães não devem desenvolver a doença
More news about: Mars Petcare
Dec 18, 2025, 11:17 ET Minaris and Cell and Gene Therapy Catapult Announce Collaboration to Advance Delivery Methods for Cell and Gene Therapies
therapeutics toward commercial manufacturing."About the Cell and Gene Therapy CatapultCell and Gene Therapy Catapult is an independent innovation and technology organisation committed to the advancement of the cell and gene therapy industry with a vision of a thriving industry delivering
More news about: Minaris Advanced Therapies
Dec 18, 2025, 11:08 ET Minaris and Cell and Gene Therapy Catapult Announce Collaboration to Advance Delivery Methods for Cell and Gene Therapies
therapeutics toward commercial manufacturing."About the Cell and Gene Therapy CatapultCell and Gene Therapy Catapult is an independent innovation and technology organisation committed to the advancement of the cell and gene therapy industry with a vision of a thriving industry delivering
More news about: Minaris Advanced Therapies
Dec 18, 2025, 09:00 ET Phoenix Children's Research Institute Secures Three Prestigious National Institutes of Health (NIH) Grants
Phoenix Children's developed nanoparticles that deliver medicine or therapeutic DNA specifically to lung cells, sparing other organs. The delivered gene, FOXM1, supports cell regeneration and repair after injury, which could prevent pulmonary hypertension and improve lung function. This exploration of
More news about: Phoenix Children's
Dec 18, 2025, 07:05 ET REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases,
More news about: REGENXBIO Inc.